An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function. - ...

Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...

A new study provides a well-needed glimmer of hope for treating Alzheimer’s disease. Focusing on a genetic form of early-onset dementia called dominantly inherited Alzheimer’s disease, scientists have ...

This article originally appeared on Undark. For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive neurodegenerative disease that is ...

They theorized that removing these proteins from the brain might delay or even reverse the disease, and they began to hunt for therapies that could do that. For decades, scientists have been testing a ...

They theorized that removing these proteins from the brain might delay or even reverse the disease, and they began to hunt for therapies that could do that. For decades, scientists have been testing a ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can delay the ...